Pharma & Healthcare
Global Checkpoint Inhibitors for Treating Cancer Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 06, 25
- ID: 291512
- Pages: 105
- Figures: 112
- Views: 28
In 2024, the global market size of Checkpoint Inhibitors for Treating Cancer was estimated to be worth US$ 19640 million and is forecast to reach approximately US$ 94850 million by 2031 with a CAGR of 25.6% during the forecast period 2025-2031.
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitors for Treating Cancer.
The Checkpoint Inhibitors for Treating Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Checkpoint Inhibitors for Treating Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitors for Treating Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Bristol-Myers Squibb(BMS)
Merck
Roche
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Checkpoint Inhibitors for Treating Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Checkpoint Inhibitors for Treating Cancer sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitors for Treating Cancer.
The Checkpoint Inhibitors for Treating Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Checkpoint Inhibitors for Treating Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitors for Treating Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Bristol-Myers Squibb(BMS)
Merck
Roche
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Checkpoint Inhibitors for Treating Cancer in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Checkpoint Inhibitors for Treating Cancer sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
1 Study Coverage
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Market by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2020-2031
2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2020-2031
2.2 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2024 Versus 2031
2.3 Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2031)
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2020-2025
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2026-2031)
2.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2020-2031)
2.4 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2020-2025
2.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2026-2031)
2.4.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2031)
3.1.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020-2031)
3.1.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2031)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2020-2031)
3.1.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2020-2031)
3.1.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2020-2031)
3.1.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2031)
3.2.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020-2031)
3.2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2031)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2020-2031)
3.2.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2020-2031)
3.2.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2020-2031)
3.2.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 PD-1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application
3.3.2 PD-L1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application
3.3.3 CTLA-4 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application
4 Global Checkpoint Inhibitors for Treating Cancer by Manufacturers
4.1 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Sales (2020-2025)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2020-2025)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (2020-2025)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2020-2025)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturer (2020-2025)
4.3 Global Checkpoint Inhibitors for Treating Cancer Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered: Ranking by Revenue
4.4.2 Global Checkpoint Inhibitors for Treating Cancer Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Product Type
4.5.1 Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
4.5.3 Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type and Application
4.5.4 PD-1 Inhibitors Market Sales of Checkpoint Inhibitors for Treating Cancer by Manufacturer
4.5.5 PD-L1 Inhibitors Market Sales of Checkpoint Inhibitors for Treating Cancer by Manufacturer
4.5.6 CTLA-4 Inhibitors Market Sales of Checkpoint Inhibitors for Treating Cancer by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bristol-Myers Squibb(BMS)
5.1.1 Bristol-Myers Squibb(BMS) Company Information
5.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview
5.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
5.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Product in 2024
5.1.6 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Application in 2024
5.1.7 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2024
5.1.8 Bristol-Myers Squibb(BMS) Recent Developments
5.2 Merck
5.2.1 Merck Company Information
5.2.2 Merck Description, Business Overview
5.2.3 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
5.2.4 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Merck Checkpoint Inhibitors for Treating Cancer Sales by Product in 2024
5.2.6 Merck Checkpoint Inhibitors for Treating Cancer Sales by Application in 2024
5.2.7 Merck Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2024
5.2.8 Merck Recent Developments
5.3 Roche
5.3.1 Roche Company Information
5.3.2 Roche Description, Business Overview
5.3.3 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
5.3.4 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Roche Checkpoint Inhibitors for Treating Cancer Sales by Product in 2024
5.3.6 Roche Checkpoint Inhibitors for Treating Cancer Sales by Application in 2024
5.3.7 Roche Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2024
5.3.8 Roche Recent Developments
6 North America
6.1 North America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
6.2 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
6.2.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
6.2.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
6.3 North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
6.4 North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Region
7.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2031)
7.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2020-2031)
7.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
7.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
8 Europe
8.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
8.2 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
8.2.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
8.2.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
8.3 Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
8.4 Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
9.2 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
9.2.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
9.2.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
9.3 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
9.4 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
10.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
10.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
10.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
10.4 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Checkpoint Inhibitors for Treating Cancer Supply Chain Analysis
11.2 Checkpoint Inhibitors for Treating Cancer Key Raw Materials and Upstream Suppliers
11.3 Checkpoint Inhibitors for Treating Cancer Clients Analysis
11.4 Checkpoint Inhibitors for Treating Cancer Sales Channel and Sales Model Analysis
11.4.1 Checkpoint Inhibitors for Treating Cancer Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Checkpoint Inhibitors for Treating Cancer Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Checkpoint Inhibitors for Treating Cancer Distributors
12 Checkpoint Inhibitors for Treating Cancer Market Dynamics
12.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
12.2 Checkpoint Inhibitors for Treating Cancer Market Drivers
12.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
12.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Market by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2020-2031
2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2020-2031
2.2 Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2024 Versus 2031
2.3 Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2031)
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2020-2025
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2026-2031)
2.3.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2020-2031)
2.4 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2020-2025
2.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2026-2031)
2.4.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2031)
3.1.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020-2031)
3.1.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2031)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2020-2031)
3.1.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2020-2031)
3.1.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2020-2031)
3.1.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2031)
3.2.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020-2031)
3.2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2031)
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2020-2031)
3.2.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2020-2031)
3.2.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2020-2031)
3.2.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 PD-1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application
3.3.2 PD-L1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application
3.3.3 CTLA-4 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application
4 Global Checkpoint Inhibitors for Treating Cancer by Manufacturers
4.1 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Sales (2020-2025)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2020-2025)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (2020-2025)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2020-2025)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturer (2020-2025)
4.3 Global Checkpoint Inhibitors for Treating Cancer Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered: Ranking by Revenue
4.4.2 Global Checkpoint Inhibitors for Treating Cancer Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Product Type
4.5.1 Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
4.5.3 Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type and Application
4.5.4 PD-1 Inhibitors Market Sales of Checkpoint Inhibitors for Treating Cancer by Manufacturer
4.5.5 PD-L1 Inhibitors Market Sales of Checkpoint Inhibitors for Treating Cancer by Manufacturer
4.5.6 CTLA-4 Inhibitors Market Sales of Checkpoint Inhibitors for Treating Cancer by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Bristol-Myers Squibb(BMS)
5.1.1 Bristol-Myers Squibb(BMS) Company Information
5.1.2 Bristol-Myers Squibb(BMS) Description, Business Overview
5.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
5.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Product in 2024
5.1.6 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Application in 2024
5.1.7 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2024
5.1.8 Bristol-Myers Squibb(BMS) Recent Developments
5.2 Merck
5.2.1 Merck Company Information
5.2.2 Merck Description, Business Overview
5.2.3 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
5.2.4 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Merck Checkpoint Inhibitors for Treating Cancer Sales by Product in 2024
5.2.6 Merck Checkpoint Inhibitors for Treating Cancer Sales by Application in 2024
5.2.7 Merck Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2024
5.2.8 Merck Recent Developments
5.3 Roche
5.3.1 Roche Company Information
5.3.2 Roche Description, Business Overview
5.3.3 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
5.3.4 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Roche Checkpoint Inhibitors for Treating Cancer Sales by Product in 2024
5.3.6 Roche Checkpoint Inhibitors for Treating Cancer Sales by Application in 2024
5.3.7 Roche Checkpoint Inhibitors for Treating Cancer Sales by Geographic Area in 2024
5.3.8 Roche Recent Developments
6 North America
6.1 North America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
6.2 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
6.2.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
6.2.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
6.3 North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
6.4 North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Region
7.2.1 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2031)
7.2.2 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2020-2031)
7.3 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
7.4 Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
8 Europe
8.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
8.2 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
8.2.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
8.2.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
8.3 Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
8.4 Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
9.2 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
9.2.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
9.2.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
9.3 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
9.4 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
10.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2031)
10.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2031)
10.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025)
10.4 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Checkpoint Inhibitors for Treating Cancer Supply Chain Analysis
11.2 Checkpoint Inhibitors for Treating Cancer Key Raw Materials and Upstream Suppliers
11.3 Checkpoint Inhibitors for Treating Cancer Clients Analysis
11.4 Checkpoint Inhibitors for Treating Cancer Sales Channel and Sales Model Analysis
11.4.1 Checkpoint Inhibitors for Treating Cancer Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Checkpoint Inhibitors for Treating Cancer Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Checkpoint Inhibitors for Treating Cancer Distributors
12 Checkpoint Inhibitors for Treating Cancer Market Dynamics
12.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
12.2 Checkpoint Inhibitors for Treating Cancer Market Drivers
12.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
12.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2025) & (K Units)
Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer (2020-2025)
Table 18. Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Price (2020-2025) & (USD/Unit)
Table 21. Ranking of Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2024)
Table 24. Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
Table 26. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Bristol-Myers Squibb(BMS) Company Information
Table 29. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 30. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
Table 31. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 32. Bristol-Myers Squibb(BMS) Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2024
Table 33. Bristol-Myers Squibb(BMS) Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2024
Table 34. Bristol-Myers Squibb(BMS) Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2024
Table 35. Bristol-Myers Squibb(BMS) Recent Developments
Table 36. Merck Company Information
Table 37. Merck Description and Business Overview
Table 38. Merck Checkpoint Inhibitors for Treating Cancer Product
Table 39. Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 40. Merck Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2024
Table 41. Merck Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2024
Table 42. Merck Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2024
Table 43. Merck Recent Developments
Table 44. Roche Company Information
Table 45. Roche Description and Business Overview
Table 46. Roche Checkpoint Inhibitors for Treating Cancer Product
Table 47. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 48. Roche Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2024
Table 49. Roche Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2024
Table 50. Roche Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2024
Table 51. Roche Recent Developments
Table 52. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 53. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 54. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 55. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 56. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 57. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 58. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2025) & (K Units)
Table 59. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2026-2031) & (K Units)
Table 60. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 61. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 62. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 63. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 64. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 65. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 66. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 67. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 68. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 69. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 70. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 71. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 72. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 73. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 74. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 75. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 76. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 77. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 78. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 79. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 80. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 81. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 82. Checkpoint Inhibitors for Treating Cancer Key Raw Materials, Industry Status and Trend
Table 83. Checkpoint Inhibitors for Treating Cancer Key Raw Materials and Upstream Suppliers
Table 84. Checkpoint Inhibitors for Treating Cancer Clients Status and Trend
Table 85. Checkpoint Inhibitors for Treating Cancer Typical Clients
Table 86. Checkpoint Inhibitors for Treating Cancer Distributors
Table 87. Checkpoint Inhibitors for Treating Cancer Market Trends
Table 88. Checkpoint Inhibitors for Treating Cancer Market Drivers
Table 89. Checkpoint Inhibitors for Treating Cancer Market Challenges
Table 90. Checkpoint Inhibitors for Treating Cancer Market Restraints
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2024 & 2031
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. CTLA-4 Inhibitors Product Picture
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2024 & 2031
Figure 9. Melanoma Treatment
Figure 10. Bladder Cancer Treatment
Figure 11. Other
Figure 12. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market Size 2020-2031 (US$ Million)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales 2020-2031 (K Units)
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2020-2031)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2020-2031)
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2020-2031)
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Type (2020-2031)
Figure 20. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2020-2031)
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2020-2031)
Figure 23. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
Figure 24. PD-1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application, 2024 VS 2031
Figure 25. PD-L1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application, 2024 VS 2031
Figure 26. CTLA-4 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application, 2024 VS 2031
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer in 2024
Figure 28. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 29. PD-1 Inhibitors Market Sales Proportion by Manufacturer in 2024
Figure 30. PD-L1 Inhibitors Market Sales Proportion by Manufacturer in 2024
Figure 31. CTLA-4 Inhibitors Market Sales Proportion by Manufacturer in 2024
Figure 32. North America Checkpoint Inhibitors for Treating Cancer Revenue 2020-2031 (US$ Million)
Figure 33. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 34. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 35. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue 2020-2031 (US$ Million)
Figure 36. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2020-2031)
Figure 37. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2020-2031)
Figure 38. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 39. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 40. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2020-2031)
Figure 42. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2020-2031)
Figure 43. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 44. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 45. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2020-2031 (US$ Million)
Figure 46. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2020-2031)
Figure 47. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2020-2025)
Figure 48. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 49. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 50. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2020-2031 (US$ Million)
Figure 51. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 54. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 55. Checkpoint Inhibitors for Treating Cancer Supply Chain (Upstream and Downstream Market)
Figure 56. Global Production Market Share of Checkpoint Inhibitors for Treating Cancer Raw Materials by Region in 2024
Figure 57. Checkpoint Inhibitors for Treating Cancer Distribution Channels
Figure 58. Global Checkpoint Inhibitors for Treating Cancer Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 59. Global Checkpoint Inhibitors for Treating Cancer Percentage 2020-2031: Online Sales VS Offline Sales
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2025) & (K Units)
Table 5. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer (2020-2025)
Table 18. Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Price (2020-2025) & (USD/Unit)
Table 21. Ranking of Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2024)
Table 24. Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
Table 26. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Bristol-Myers Squibb(BMS) Company Information
Table 29. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 30. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
Table 31. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 32. Bristol-Myers Squibb(BMS) Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2024
Table 33. Bristol-Myers Squibb(BMS) Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2024
Table 34. Bristol-Myers Squibb(BMS) Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2024
Table 35. Bristol-Myers Squibb(BMS) Recent Developments
Table 36. Merck Company Information
Table 37. Merck Description and Business Overview
Table 38. Merck Checkpoint Inhibitors for Treating Cancer Product
Table 39. Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 40. Merck Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2024
Table 41. Merck Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2024
Table 42. Merck Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2024
Table 43. Merck Recent Developments
Table 44. Roche Company Information
Table 45. Roche Description and Business Overview
Table 46. Roche Checkpoint Inhibitors for Treating Cancer Product
Table 47. Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
Table 48. Roche Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Product in 2024
Table 49. Roche Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Application in 2024
Table 50. Roche Sales Proportion of Checkpoint Inhibitors for Treating Cancer by Geographic Area in 2024
Table 51. Roche Recent Developments
Table 52. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 53. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 54. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 55. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 56. North America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 57. North America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 58. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2020-2025) & (K Units)
Table 59. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2026-2031) & (K Units)
Table 60. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2020-2025) & (US$ Million)
Table 61. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2026-2031) & (US$ Million)
Table 62. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 63. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 64. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 65. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 66. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 67. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 68. Europe Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 69. Europe Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 70. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 71. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 72. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 73. Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 74. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 75. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 76. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2020-2025) & (K Units)
Table 77. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2026-2031) & (K Units)
Table 78. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2020-2025) & (US$ Million)
Table 79. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2026-2031) & (US$ Million)
Table 80. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Type (2020-2025) & (K Units)
Table 81. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Application (2020-2025) & (K Units)
Table 82. Checkpoint Inhibitors for Treating Cancer Key Raw Materials, Industry Status and Trend
Table 83. Checkpoint Inhibitors for Treating Cancer Key Raw Materials and Upstream Suppliers
Table 84. Checkpoint Inhibitors for Treating Cancer Clients Status and Trend
Table 85. Checkpoint Inhibitors for Treating Cancer Typical Clients
Table 86. Checkpoint Inhibitors for Treating Cancer Distributors
Table 87. Checkpoint Inhibitors for Treating Cancer Market Trends
Table 88. Checkpoint Inhibitors for Treating Cancer Market Drivers
Table 89. Checkpoint Inhibitors for Treating Cancer Market Challenges
Table 90. Checkpoint Inhibitors for Treating Cancer Market Restraints
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources
Table 94. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2024 & 2031
Figure 4. PD-1 Inhibitors Product Picture
Figure 5. PD-L1 Inhibitors Product Picture
Figure 6. CTLA-4 Inhibitors Product Picture
Figure 7. Global Checkpoint Inhibitors for Treating Cancer Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2024 & 2031
Figure 9. Melanoma Treatment
Figure 10. Bladder Cancer Treatment
Figure 11. Other
Figure 12. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market Size 2020-2031 (US$ Million)
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales 2020-2031 (K Units)
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2020-2031)
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2020-2031)
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2020-2031)
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Type (2020-2031)
Figure 20. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2020-2025) & (USD/Unit)
Figure 21. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2020-2031)
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2020-2031)
Figure 23. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2020-2025) & (USD/Unit)
Figure 24. PD-1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application, 2024 VS 2031
Figure 25. PD-L1 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application, 2024 VS 2031
Figure 26. CTLA-4 Inhibitors of Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application, 2024 VS 2031
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer in 2024
Figure 28. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 29. PD-1 Inhibitors Market Sales Proportion by Manufacturer in 2024
Figure 30. PD-L1 Inhibitors Market Sales Proportion by Manufacturer in 2024
Figure 31. CTLA-4 Inhibitors Market Sales Proportion by Manufacturer in 2024
Figure 32. North America Checkpoint Inhibitors for Treating Cancer Revenue 2020-2031 (US$ Million)
Figure 33. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 34. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 35. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue 2020-2031 (US$ Million)
Figure 36. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2020-2031)
Figure 37. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2020-2031)
Figure 38. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 39. Asia-Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 40. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2020-2031 (US$ Million)
Figure 41. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2020-2031)
Figure 42. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2020-2031)
Figure 43. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 44. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 45. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2020-2031 (US$ Million)
Figure 46. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2020-2031)
Figure 47. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2020-2025)
Figure 48. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 49. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 50. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2020-2031 (US$ Million)
Figure 51. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2020-2031)
Figure 52. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2020-2025)
Figure 54. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2020-2025)
Figure 55. Checkpoint Inhibitors for Treating Cancer Supply Chain (Upstream and Downstream Market)
Figure 56. Global Production Market Share of Checkpoint Inhibitors for Treating Cancer Raw Materials by Region in 2024
Figure 57. Checkpoint Inhibitors for Treating Cancer Distribution Channels
Figure 58. Global Checkpoint Inhibitors for Treating Cancer Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 59. Global Checkpoint Inhibitors for Treating Cancer Percentage 2020-2031: Online Sales VS Offline Sales
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Natural Cocoa Extracts Market Research Report 2026
May 01, 26
Global Semiconductor Switched Mode Power Supply Market Research Report 2026
May 01, 26
Global Silicone Coated Spandrel Glass Market Research Report 2026
May 01, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232